OTCM
BIEL
Market cap3mUSD
Jul 18, Last price
0.00USD
1D
0.00%
1Q
-33.33%
Jan 2017
-42.86%
IPO
-99.97%
Name
BioElectronics Corp
Chart & Performance
Profile
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 715 1.03% | 707 -56.05% | |||||||
Cost of revenue | 521 | 454 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 194 | 254 | |||||||
NOPBT Margin | 27.14% | 35.85% | |||||||
Operating Taxes | (168) | (228) | |||||||
Tax Rate | |||||||||
NOPAT | 362 | 482 | |||||||
Net income | (723) -7.91% | (785) 170.83% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 2,302 | 1,898 | |||||||
Long-term debt | 12,530 | 12,191 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 14,827 | 14,044 | |||||||
Cash flow | |||||||||
Cash from operating activities | (336) | (479) | |||||||
CAPEX | 1 | ||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 296 | 523 | |||||||
FCF | 343 | 373 | |||||||
Balance | |||||||||
Cash | 5 | 45 | |||||||
Long term investments | |||||||||
Excess cash | 10 | ||||||||
Stockholders' equity | (16,478) | 7,580 | |||||||
Invested Capital | 14,831 | (1,676) | |||||||
ROIC | 5.50% | 7.50% | |||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 24,705,067 | 24,541,948 | |||||||
Price | 0.00 -60.00% | 0.00 -52.38% | |||||||
Market cap | 4,941 -59.73% | 12,271 -51.82% | |||||||
EV | 19,768 | 26,315 | |||||||
EBITDA | 194 | 254 | |||||||
EV/EBITDA | 101.93 | 103.77 | |||||||
Interest | 449 | 441 | |||||||
Interest/NOPBT | 231.27% | 174.08% |